WHO in November last year issued an emergency use listing (EUL) for COVAXIN, adding to a growing portfolio of vaccines validated for the prevention of COVID-19 caused by SARS-CoV-2
"We're extremely pleased that we can proceed with our clinical trials for Covaxin our whole virus inactivated COVID-19 vaccine candidate," Dr Shankar Musunuri, CEO and Co-Founder, Ocugen Inc said
A senior government official had told Business Standard last week that so far there was no scientific evidence to expand the vaccination programme to young children
Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that Bharat Biotech addresses the issue immediately to avoid the cancellation
This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years
WHO had earlier suspended the supply of Covaxin through US procurement agencies, after its inspectors identified GMP (good manufacturing practice) deficiencies in the Bharat Biotech's plants
Vaccine majors SII and Bharat Biotech said they have decided to cut prices of precaution dose of their respective Covid-19 vaccines to Rs 225 per shot for private hospitals after discussion with govt
A recent ICMR study has shown that breakthrough cases after full vaccination with Covaxin have shown a significant increase in the immune response against coronavirus' variants of concern
Bharat biotech says there are no issues with Covaxin or its certification, further we will focus on pending facility maintenance, has no supply commitments pending for UN agency.
'For the coming period, the company will focus on pending facility maintenance, process and facility optimization activities,' the Hyderabad-based company said
